160P Cabozantinib in late-line therapy for metastatic Ewing sarcoma: A single-center experience
ESMO Rare Cancers · 2026-03 · 5 · 100366
DOI: 10.1016/j.esmorc.2026.100366 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESMO Rare Cancers, 2026-03. Verfasst von P. Jagodzinska-Mucha und 7 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Jagodzinska-Mucha, P., Teterycz, P., Rogala, P., Kozak, K., Paterczyk, H. K., Chmiel, P., Mariuk-Jarema, A., & Rutkowski, P. (2026). 160P Cabozantinib in late-line therapy for metastatic Ewing sarcoma: A single-center experience. ESMO Rare Cancers, 5, 100366. https://doi.org/10.1016/j.esmorc.2026.100366
Vancouver
Jagodzinska-Mucha P, Teterycz P, Rogala P, Kozak K, Paterczyk HK, Chmiel P, et al. 160P Cabozantinib in late-line therapy for metastatic Ewing sarcoma: A single-center experience. ESMO Rare Cancers. 2026;5:100366. doi:10.1016/j.esmorc.2026.100366
BibTeX
@article{JagodzinskaMucha2026,
author = {Jagodzinska-Mucha, P. and Teterycz, P. and Rogala, P. and Kozak, K. and Paterczyk, H.M. Kosela and Chmiel, P. and Mariuk-Jarema, A. and Rutkowski, P.},
title = {160P Cabozantinib in late-line therapy for metastatic Ewing sarcoma: A single-center experience},
journal = {ESMO Rare Cancers},
year = {2026},
volume = {5},
pages = {100366},
doi = {10.1016/j.esmorc.2026.100366}
}
EUVIMED